Quantcast
Last updated on April 16, 2014 at 5:31 EDT

Latest Mylan Inc. Stories

2014-01-09 08:27:16

PITTSBURGH, Jan. 9, 2014 /PRNewswire/ -- Mylan, Inc. (Nasdaq: MYL) today announced that Zyomyx's MyT4(TM) point-of-care CD4 diagnostic test has received the CE Certificate of Conformity in the European Union, an important step toward launching this innovative test and expanding access to affordable, accessible and reliable diagnostics for people living with HIV globally. As a result, the MyT4(TM) CD4 test can now bear the CE Mark, which demonstrates that the MyT4(TM) CD4 test complies...

2014-01-09 08:26:46

- Company awarded 180 days marketing exclusivity on the 360 mg strength - PITTSBURGH, Jan. 9, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Mycophenolic Acid Delayed-release Tablets, 180 mg and 360 mg. This product is the generic version of Novartis' Myfortic(®) Delayed-release Tablets. Mylan was the first company to have filed a substantially complete Abbreviated New Drug Application (ANDA)...

2014-01-08 16:25:55

PITTSBURGH, Jan. 8, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the appointment of Adele Gulfo as executive vice president, Global Collaboration and Strategic Operations. Gulfo will serve as a member of Mylan's executive leadership team. Prior to joining Mylan, Gulfo served as regional president of Latin America in Pfizer's Emerging Markets Business Unit. In this capacity, she led a team of over 4,000 colleagues operating across more than 23 countries. In 2012,...

2014-01-07 16:25:11

PITTSBURGH, Jan. 7, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release (ER) Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol® LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug...

2014-01-02 12:23:05

PITTSBURGH, Jan. 2, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the Company will present at the J.P. Morgan 32(nd) Annual Healthcare Conference on Tuesday Jan. 14, 2014, in San Francisco. The presentation is scheduled to begin at 7:30 p.m. ET on Tuesday Jan. 14, 2014. Interested parties can access a live webcast of the presentation via the investor relations section of Mylan's Web...

2014-01-02 12:22:33

PITTSBURGH, Jan. 2, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that CEO Heather Bresch will present at the Goldman Sachs Healthcare CEOs Unscripted: A View From the Top Conference on Tuesday Jan. 7, 2014, in Boston. The presentation is scheduled to begin at 8:45 a.m. ET on Tuesday Jan. 7, 2014. Interested parties can access a live webcast of the presentation via the investor relations...

2014-01-02 12:22:28

PITTSBURGH, Jan. 2, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that Rakesh Bamzai has joined the company and has been appointed president, India Commercial and Emerging Markets. Bamzai has more than 20 years of experience in the Indian and global biopharmaceutical industry. Prior to joining Mylan, he was president of Marketing at Biocon, where he played a key role in building the company's global biopharmaceutical business. He had overall responsibility for active...

2013-12-18 12:25:21

PITTSBURGH, Dec. 18, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has received all regulatory approvals and has completed an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist (LAMA) compound for various indications. Mylan expects that this product, which is ready to enter Phase IIb, will be submitted to the U.S. Food and Drug Administration (FDA) for approval as a new...

2013-12-17 16:23:22

Agreement includes a no-later-than July 9, 2015 launch PITTSBURGH, Dec. 17, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. and partner, Banner Pharmacaps Inc. (a wholly-owned subsidiary of Patheon Inc.), have entered into a settlement and license agreement with Eisai Inc. and Valeant Pharmaceuticals Luxembourg S.a.r.l that will resolve patent litigation related to Bexarotene Capsules, 75 mg. Bexarotene is the generic...

2013-12-05 08:29:16

PITTSBURGH, Dec. 5, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Cabergoline Tablets USP, 0.5 mg. Cabergoline Tablets USP are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Cabergoline Tablets...